Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality and
has an increasing incidence worldwide. Locoregional therapies, defined as imaging-guided …

In contrast to most other malignancies, hepatocellular carcinoma (HCC), which accounts for
approximately 90% of primary liver cancers, arises almost exclusively in the setting of …

Background & Aims Tremelimumab is a fully human monoclonal antibody that binds to
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on the surface of activated T …

Immune associated cells in the microenvironment have a significant impact on the
development and progression of hepatocellular carcinoma (HCC) and have received more …

Minimally invasive thermal ablation of tumours has become common since the advent of
modern imaging. From the ablation of small, unresectable tumours to experimental …

Background Modulation of adaptive immunity may underscore the efficacy of trans-arterial
chemoembolization (TACE). We evaluated the influence of TACE on T-cell function by …

Introduction: Atezolizumab plus bevacizumab therapy is extremely effective in the treatment
of intermediate-stage hepatocellular carcinoma (HCC), with a response rate of 44%, as …

Although systemic immunotherapy has achieved durable responses and improved survival
for certain patients and cancer types, low response rates and immune system-related …

Atezolizumab plus bevacizumab (Atezo/Bev) followed by curative conversion (ABC
conversion) therapy is very effective in the treatment of unresectable, transarterial …

Sonodynamic therapy (SDT) represents an emerging approach that offers the possibility of
non-invasively eradicating solid tumors in a site-directed manner. It involves the …